BioCryst's BCX4208 study results in gout to be presented at EULAR meeting

Download PDF Copy

Apr 22 2011

NewsGuard 100/100 Score

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced the presentation of clinical results related to BCX4208 for the treatment of gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in London, England.

The data related to BCX4208 will be presented during a poster session scheduled for Thursday, May 26, 2011 from 8:00-3:30 p.m. GMT. The two posters to be presented during the session include:

Presentation Number THR0027: "BCX4208, A Novel Urate-Lowering Therapy, was Generally Safe and Well-Tolerated in Two 3-Week Studies in Gout Subjects"
Presentation Number THU0011: "BCX4208 Shows Synergistic Reductions in Serum Uric Acid (sUA) in Gout Patients when Combined with Allopurinol"

Source: http://www.biocryst.com/

Posted in: Drug Trial News | Medical Condition News

Tags: Allopurinol, Cancer, Gout, Influenza, Pharmaceuticals, Rheumatism, Rheumatology, Uric Acid

Comments (0)

Download PDF Copy

Suggested Reading

Combination therapy shows promising results in treating stage 3 melanoma

Combination therapy shows promising results in treating stage 3 melanoma

California expanded Medi-Cal to unauthorized residents. The results are mixed.

California expanded Medi-Cal to unauthorized residents. The results are mixed.

Antibiotic resistance threatens millions of lives worldwide

Antibiotic resistance threatens millions of lives worldwide

Study shows how a single defective BRCA1 gene accelerates cancer development

Study shows how a single defective BRCA1 gene accelerates cancer development

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Genetics identified as key factor in gout development

Genetics identified as key factor in gout development

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Obesity crisis in the U.S. expected to worsen by 2050